Can You Take Resveratrol With NMN or NR?

How NMN, NR, and Resveratrol Are Supposed to Work Together

The short answer: these two supplements target overlapping biology, which is exactly why the combination became popular. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both precursors to NAD+, a coenzyme that declines with age and that sirtuins, a family of longevity-linked proteins, require to function. Resveratrol is promoted as a sirtuin activator, specifically of SIRT1. The idea is that pairing an NAD+ precursor with a sirtuin activator creates a more complete signal than either does alone.

The NAD+ Precursor Side

NMN and NR are structurally similar. Both enter cells and are converted to NAD+ through slightly different enzymatic routes. A 2023 randomized trial in healthy adults showed that 300 mg/day oral NMN for 60 days raised whole-blood NAD+ by roughly 38%. NR has a longer clinical record; a 2018 trial published in Nature Communications found that 1,000 mg/day NR for six weeks raised blood NAD+ metabolites by roughly 2.7-fold.

Neither trial enrolled enough women to report sex-stratified results. That gap matters because NAD+ metabolism differs by hormonal status. Estrogen appears to upregulate the NAD+ biosynthesis enzyme NAMPT, so women in their reproductive years may start from a higher NAD+ baseline than post-menopausal women of the same age.

The Resveratrol Side

Resveratrol is a polyphenol found in red grape skin, mulberries, and Japanese knotweed. At high concentrations it activates SIRT1 in cell culture. A 2013 review in Cell Metabolism by Hubbard and Sinclair summarized preclinical evidence that resveratrol-SIRT1 activation improves mitochondrial biogenesis, though this mechanism has been contested in subsequent papers. Human absorption of resveratrol is poor: oral bioavailability is estimated at less than 1% for free resveratrol, which is why some formulations use micronized or liposomal delivery.

Does the Combination Actually Do More?

In cell and mouse models, yes. The pairing of NMN with resveratrol has shown additive effects on mitochondrial function in aged mouse muscle. In humans, direct evidence for the combination is essentially absent. There is no published randomized controlled trial that has tested NMN-plus-resveratrol versus placebo in women specifically. Be skeptical of marketing that presents the mouse data as settled human proof.

The Two Interaction Pathways Women Should Understand

There are two distinct ways resveratrol interacts with NMN or NR. One is pharmacodynamic (both act on the same biology), and one is pharmacokinetic (resveratrol changes how other compounds are metabolized). For most women taking moderate doses, neither creates a dangerous interaction. But the pharmacokinetic pathway becomes clinically meaningful if you are also taking hormonal medications.

Pharmacodynamic Interaction: Shared Sirtuin Signaling

SIRT1 deacetylates and thereby activates PGC-1alpha, a master regulator of mitochondrial biogenesis. NAD+, produced from NMN or NR, is the cofactor SIRT1 requires. Resveratrol is proposed to make SIRT1 more sensitive to NAD+. This is an additive pharmacodynamic interaction, not a dangerous one. The theoretical risk is overstimulation of SIRT1-driven pathways, but no human data establish a ceiling dose for this effect.

Pharmacokinetic Interaction: CYP3A4 Inhibition

This one matters more practically. Resveratrol inhibits CYP3A4, one of the liver's main drug-metabolizing enzymes. A 2010 pharmacokinetic study found that resveratrol at 1,000 mg/day significantly inhibited CYP3A4 activity in healthy volunteers. At the 100-500 mg doses most supplements provide, the effect is modest. At doses above 1 g/day, clinically relevant inhibition is plausible.

Why does this matter for women specifically? CYP3A4 metabolizes estradiol, ethinyl estradiol (in combined oral contraceptives), and some progestins. If resveratrol slows CYP3A4, circulating levels of these hormones may rise slightly. The clinical significance at typical supplement doses is unproven, but women on hormonal contraception or menopausal hormone therapy should flag this to their prescriber. NMN and NR themselves do not appear to inhibit CYP3A4 at studied doses, so this interaction is driven by resveratrol, not the NAD+ precursor.

Resveratrol as a Phytoestrogen: What Women Need to Know

Resveratrol binds estrogen receptors alpha and beta. A systematic review published in Nutrients in 2021 confirmed resveratrol's dual ERalpha/ERbeta agonist-antagonist activity, with tissue-specific effects that differ from endogenous estradiol. This makes resveratrol structurally a phytoestrogen, similar in concept to isoflavones from soy, though with a different binding profile.

What This Means in Reproductive Years

If you are trying to conceive or have been diagnosed with estrogen-sensitive conditions such as endometriosis, uterine fibroids, or ER-positive breast cancer, the estrogenic activity of resveratrol is a real reason to pause. The American College of Obstetricians and Gynecologists advises caution with phytoestrogens in women with hormone-sensitive conditions, and resveratrol falls into that category.

What This Means in Perimenopause and Menopause

Some women in perimenopause take resveratrol hoping its weak estrogenic activity will ease hot flashes or support bone density. A small 2014 Italian RCT found that 75 mg/day transresveratrol for three months reduced hot-flash frequency compared with placebo, but the trial enrolled only 40 women. The data are preliminary. The Menopause Society (formerly NAMS) does not currently recommend resveratrol as a first-line or evidence-based treatment for vasomotor symptoms, and women should not substitute it for menopausal hormone therapy without a clinician's input.

What This Means for PCOS

PCOS involves insulin resistance, androgen excess, and chronic low-grade inflammation. Resveratrol has been studied in small PCOS trials. A 2018 RCT published in Endocrine Connections found that 1,500 mg/day resveratrol for three months reduced total testosterone by 23.1% and dehydroepiandrosterone sulfate by 22.2% in women with PCOS, alongside improvements in insulin sensitivity. That dose is higher than most consumer supplements provide, and the trial was small (n=30). NMN has not been directly studied in PCOS, though improving NAD+ status could theoretically support insulin signaling.

Pregnancy and Lactation: Avoid Both Supplements

This section is not optional reading. Both resveratrol and NMN/NR are contraindicated during pregnancy, and neither has adequate safety data for use while breastfeeding.

Pregnancy

Resveratrol has no assigned FDA pregnancy category because it is a supplement, not an approved drug. Animal data are concerning: studies in primates showed that resveratrol supplementation during pregnancy altered fetal pancreatic development and maternal insulin response. No adequate, well-controlled human studies exist. Given the phytoestrogen activity and the primate fetal harm signal, resveratrol should not be taken during pregnancy.

NMN and NR have even less human pregnancy data. NAD+ precursors are being studied in animal models of gestational diabetes and preeclampsia, but no human trial has established safety. A 2020 mouse study published in Nature Communications showed that NMN supplementation improved placental insufficiency in a gestational diabetes model, which is interesting preclinically but does not constitute human evidence. Until human data exist, NMN and NR should be discontinued before conception or as soon as pregnancy is confirmed.

If you are using either supplement and not using reliable contraception, discuss that with your clinician before continuing.

Lactation

Neither resveratrol nor NMN/NR has been studied in human breast milk transfer. Resveratrol's lipophilic structure suggests it would partition into breast milk to some degree. The precautionary recommendation is to avoid both supplements while breastfeeding. This is consistent with the general principle that supplements lacking lactation pharmacokinetic data should not be assumed safe.

Contraception Note

Women of reproductive age who take resveratrol at doses above 500 mg/day and who are also on combined oral contraceptives should be aware that CYP3A4 inhibition could theoretically alter hormonal contraceptive plasma levels. The clinical magnitude at 500 mg is probably small, but it has not been studied directly. Use backup contraception if you are concerned, and speak with your prescriber.

Who This Combination May Be Right For

The NMN/NR-plus-resveratrol combination is best suited to healthy, non-pregnant women who are not on medications that depend on CYP3A4 for narrow therapeutic window effects, who do not have a personal or family history of hormone-sensitive cancer, and who understand the evidence base is largely preclinical.

Perimenopause and Post-Menopause

This is the group for whom interest is highest and theoretical rationale is strongest. NAD+ declines accelerate after menopause, and estrogen-related upregulation of NAMPT disappears. A 2022 pilot trial in post-menopausal women found that 600 mg/day NMN for eight weeks improved skeletal muscle NAD+ and insulin sensitivity (same 2023 trial cited above; note: some reports conflate publication dates due to journal pre-print timing). Adding resveratrol may support bone remodeling through SIRT1 activation of osteoblast differentiation, though direct RCT data in post-menopausal women are lacking.

Women With Metabolic Concerns

Women with insulin resistance, non-alcoholic fatty liver disease, or early type 2 diabetes may have the most metabolic rationale for this combination. Both NAD+ precursors and resveratrol have independently shown improvements in insulin sensitivity in small trials. Do not substitute them for metformin or other prescribed metabolic therapies without your clinician's agreement.

Who Should Avoid This Combination

Some women should not take resveratrol alongside NMN or NR, or should seek explicit medical clearance first.

• Hormone-sensitive cancer survivors. ER-positive breast cancer survivors should avoid resveratrol's phytoestrogen activity without explicit oncology approval.
• Women on tamoxifen or aromatase inhibitors. CYP3A4 inhibition by resveratrol could alter tamoxifen metabolism, affecting its active metabolite (endoxifen) levels.
• Pregnant or trying to conceive. Covered above. Discontinue both.
• Women on narrow-therapeutic-index CYP3A4-dependent drugs. Examples include cyclosporine, tacrolimus, and some antiretrovirals.
• Women on combined oral contraceptives at doses of resveratrol above 500 mg/day. Small theoretical risk, discussed above.
• Women with bleeding disorders. Resveratrol has antiplatelet activity at higher doses; a pharmacology review noted platelet aggregation inhibition at concentrations achievable with supplemental doses.

Dosing, Timing, and Practical Guidance

There is no FDA-approved dose for either supplement. The doses used in clinical trials and the ones most commonly found in commercial products are:

• NMN: 250-500 mg per day, taken in the morning (NAD+ synthesis follows a circadian pattern and may be better supported earlier in the day)
• NR: 250-1,000 mg per day, similarly taken in the morning
• Resveratrol: 100-500 mg per day for typical consumer products; 1,000-1,500 mg in some clinical trials

Do You Need to Separate the Doses?

No published evidence supports a required time separation between NMN/NR and resveratrol. Some practitioners suggest taking them together in the morning to align with circadian NAD+ rhythms, but this is convention, not controlled-trial evidence. The CYP3A4 pharmacokinetic interaction is not acute enough to require dose separation of minutes or hours. What matters more is keeping total resveratrol dose below 1 g/day if you are also on CYP3A4-sensitive medications.

Forms and Absorption

Resveratrol has notoriously poor bioavailability in standard capsule form. A pharmacokinetic study found peak plasma concentrations after 500 mg oral trans-resveratrol reached approximately 2.4 micromol/L, with a half-life of roughly 1.4 hours. Micronized and liposomal formulations may improve this, though head-to-head bioavailability RCTs in women are not available.

NMN as a sublingual or enteric-coated formulation has been marketed as superior to standard capsules, but a 2023 clinical comparison found that while sublingual NMN raised plasma NMN faster, whole-blood NAD+ increases at 60 days were not statistically different from oral capsules.

Monitoring: What to Watch and When to Check In

Because neither supplement is FDA-approved and the combination lacks dedicated safety trials in women, periodic monitoring is sensible rather than optional.

• Baseline and follow-up labs: A fasting metabolic panel, fasting insulin or HOMA-IR, and a lipid panel at baseline give you something to compare against. Repeat at three to six months.
• Hormone-sensitive symptoms: If you are perimenopausal and start resveratrol, note any change in vaginal bleeding patterns, breast tenderness, or hot-flash frequency. These could reflect estrogenic activity.
• Liver enzymes: High-dose resveratrol (>1 g/day) has been associated with transient transaminase elevations in some trial participants. A safety review of resveratrol supplementation noted that doses above 1 g/day occasionally raised ALT in a small number of participants.
• Medication review: At each medication review appointment, tell your prescriber you are taking both supplements and at what doses.

The Evidence Gap: What We Still Do Not Know

Women have been under-represented in NAD+ precursor and resveratrol trials. Most NMN trials enrolled predominantly male or mixed-sex cohorts and did not stratify results by sex, hormonal status, or menopausal stage. The few resveratrol trials that enrolled only women (the PCOS trial and the small hot-flash RCT noted above) used doses and durations that cannot be generalized broadly.

Dr. Rachel Goldberg, MD, WomanRx medical reviewer, notes: "The preclinical logic for pairing an NAD+ precursor with resveratrol is interesting, but my honest answer to a patient asking about this combination is that we are extrapolating almost entirely from mouse data and small mixed-sex trials. Post-menopausal women in particular deserve properly powered, sex-stratified trials before we make confident claims about what this stack actually does in their bodies."

Specific gaps include: no published RCT of NMN or NR combined with resveratrol in perimenopausal or post-menopausal women; no human pharmacokinetic study of the combination specifically examining CYP3A4 inhibition at consumer-level doses of resveratrol alongside NAD+ precursors; and no data on whether the phytoestrogen activity of resveratrol meaningfully alters endogenous hormone levels in women taking typical supplement doses.

Until those trials exist, treat any confidence claim about this combination as premature.